1	Genentech	NNP	2	nn
2	Inc.	NNP	3	nsubj
3	said	VBD	0	root
4	third-quarter	JJ	5	amod
5	profit	NN	8	nsubj
6	more	RBR	7	advmod
7	than	IN	8	advmod
8	doubled	VBD	3	ccomp
9	to	TO	8	prep
10	$	$	9	pobj
11	11.4	CD	10	number
12	million	CD	10	number
13	,	,	10	punct
14	or	CC	10	cc
15	13	CD	16	num
16	cents	NNS	10	conj
17	a	DT	18	det
18	share	NN	16	npadvmod
19	,	,	10	punct
20	from	IN	8	prep
21	a	DT	25	det
22	depressed	JJ	25	amod
23	1988	CD	25	nn
24	third-quarter	JJ	23	amod
25	performance	NN	20	pobj
26	of	IN	25	prep
27	$	$	26	pobj
28	5.3	CD	27	number
29	million	CD	27	number
30	,	,	27	punct
31	or	CC	27	cc
32	six	CD	33	num
33	cents	NNS	27	conj
34	a	DT	35	det
35	share	NN	33	npadvmod
36	.	.	3	punct

1	Revenue	NN	2	nsubj
2	rose	VBD	0	root
3	23	CD	4	num
4	%	NN	2	dobj
5	to	TO	2	prep
6	$	$	5	pobj
7	100	CD	6	number
8	million	CD	6	number
9	from	IN	2	prep
10	$	$	9	pobj
11	81.6	CD	10	number
12	million	CD	10	number
13	.	.	2	punct

1	Net	JJ	3	amod
2	product	NN	3	nn
3	sales	NNS	4	nsubj
4	accounted	VBD	0	root
5	for	IN	4	prep
6	$	$	5	pobj
7	76	CD	6	number
8	million	CD	6	number
9	,	,	4	punct
10	up	RB	4	advmod
11	from	IN	10	prep
12	$	$	11	pobj
13	57.5	CD	12	number
14	million	CD	12	number
15	a	DT	16	det
16	year	NN	17	npadvmod
17	earlier	RB	11	advmod
18	.	.	4	punct

1	Sales	NNS	8	nsubj
2	of	IN	1	prep
3	the	DT	5	det
4	heart	NN	5	nn
5	drug	NN	6	nn
6	TPA	NNP	2	pobj
7	were	VBD	8	cop
8	$	$	0	root
9	43.6	CD	8	number
10	million	CD	8	number
11	,	,	8	punct
12	better	JJR	8	amod
13	than	IN	12	prep
14	last	JJ	15	amod
15	year	NN	19	poss
16	's	POS	15	possessive
17	depressed	JJ	19	amod
18	third	JJ	19	amod
19	period	NN	13	pobj
20	when	WRB	23	advmod
21	the	DT	22	det
22	company	NN	23	nsubj
23	sold	VBD	19	dep
24	just	RB	25	quantmod
25	$	$	23	dobj
26	29.1	CD	25	number
27	million	CD	25	number
28	of	IN	25	prep
29	the	DT	30	det
30	drug	NN	28	pobj
31	.	.	8	punct

1	But	CC	4	cc
2	TPA	NNP	3	nn
3	sales	NNS	4	nsubj
4	fell	VBD	0	root
5	below	IN	4	prep
6	levels	NNS	5	pobj
7	for	IN	6	prep
8	this	DT	9	det
9	year	NN	15	poss
10	's	POS	9	possessive
11	first	JJ	15	amod
12	and	CC	11	cc
13	second	JJ	11	conj
14	quarter	NN	15	nn
15	sales	NNS	7	pobj
16	of	IN	15	prep
17	$	$	16	pobj
18	48	CD	17	number
19	million	CD	17	number
20	,	,	4	punct
21	cooling	VBG	4	xcomp
22	investors	NNS	21	dobj
23	.	.	4	punct

1	Genentech	NNP	2	nn
2	stock	NN	3	nsubj
3	fell	VBD	0	root
4	12.5	CD	5	num
5	cents	NNS	3	dobj
6	in	IN	3	prep
7	trading	NN	6	pobj
8	yesterday	NN	7	tmod
9	on	IN	7	prep
10	the	DT	14	det
11	New	NNP	12	nn
12	York	NNP	14	nn
13	Stock	NNP	14	nn
14	Exchange	NNP	9	pobj
15	to	TO	3	prep
16	$	$	15	pobj
17	20.125	CD	16	num
18	.	.	3	punct

1	In	IN	8	prep
2	the	DT	4	det
3	nine	CD	4	num
4	months	NNS	1	pobj
5	,	,	8	punct
6	net	JJ	7	amod
7	income	NN	8	nsubj
8	slid	VBD	0	root
9	21	CD	10	num
10	%	NN	8	npadvmod
11	to	TO	8	prep
12	$	$	11	pobj
13	28.4	CD	12	number
14	million	CD	12	number
15	,	,	12	punct
16	or	CC	12	cc
17	33	CD	18	num
18	cents	NNS	12	conj
19	a	DT	20	det
20	share	NN	18	npadvmod
21	,	,	12	punct
22	from	IN	8	prep
23	$	$	22	pobj
24	36	CD	23	number
25	million	CD	23	number
26	,	,	23	punct
27	or	CC	23	cc
28	42	CD	29	num
29	cents	NNS	23	conj
30	a	DT	31	det
31	share	NN	29	npadvmod
32	.	.	8	punct

1	Revenues	NNS	2	nsubj
2	climbed	VBD	0	root
3	18	CD	4	num
4	%	NN	2	dobj
5	to	TO	2	prep
6	$	$	5	pobj
7	289	CD	6	number
8	million	CD	6	number
9	from	IN	2	prep
10	$	$	9	pobj
11	245.3	CD	10	number
12	million	CD	10	number
13	.	.	2	punct

1	``	``	22	punct
2	We	PRP	3	nsubj
3	continue	VBP	22	ccomp
4	to	TO	5	aux
5	be	VB	3	xcomp
6	on	IN	5	prep
7	target	NN	6	pobj
8	for	IN	5	prep
9	...	:	8	punct
10	increasing	VBG	8	dep
11	TPA	NNP	12	nn
12	sales	NNS	10	iobj
13	20	CD	14	num
14	%	NN	10	dobj
15	to	TO	14	prep
16	25	CD	17	num
17	%	NN	15	pobj
18	this	DT	19	det
19	year	NN	10	dep
20	,	,	22	punct
21	''	''	22	punct
22	said	VBD	0	root
23	founder	NN	29	nn
24	and	CC	23	cc
25	Chief	NNP	27	nn
26	Executive	NNP	27	nn
27	Officer	NNP	23	conj
28	Robert	NNP	29	nn
29	Swanson	NNP	22	nsubj
30	.	.	22	punct

1	But	CC	5	cc
2	some	DT	3	det
3	analysts	NNS	5	nsubj
4	remain	VBP	5	cop
5	sour	JJ	0	root
6	on	IN	5	prep
7	the	DT	8	det
8	company	NN	6	pobj
9	.	.	5	punct

1	``	``	4	punct
2	TPA	NNP	3	nn
3	sales	NNS	4	nsubj
4	are	VBP	0	root
5	down	RB	4	advmod
6	quarter	NN	4	tmod
7	to	TO	6	prep
8	quarter	NN	7	pobj
9	.	.	4	punct

1	Expenses	NNS	3	nsubj
2	are	VBP	3	cop
3	flat	JJ	0	root
4	and	CC	3	cc
5	that	DT	9	nsubj
6	's	VBZ	9	cop
7	a	DT	9	det
8	good	JJ	9	amod
9	sign	NN	3	conj
10	.	.	3	punct

1	There	EX	2	expl
2	's	VBZ	0	root
3	contract	NN	4	nn
4	revenue	NN	2	nsubj
5	from	IN	4	prep
6	-LCB-	-LRB-	8	punct
7	limited	JJ	8	amod
8	research	NN	12	nn
9	and	CC	8	cc
10	development	NN	8	conj
11	-RCB-	-RRB-	8	punct
12	partnerships	NNS	5	pobj
13	.	.	2	punct

1	But	CC	4	cc
2	I	PRP	4	nsubj
3	still	RB	4	advmod
4	think	VBP	11	ccomp
5	the	DT	6	det
6	fundamentals	NNS	8	nsubj
7	are	VBP	8	cop
8	poor	JJ	4	ccomp
9	,	,	11	punct
10	''	''	11	punct
11	said	VBD	0	root
12	Denise	NNP	13	nn
13	Gilbert	NNP	11	nsubj
14	,	,	13	punct
15	an	DT	16	det
16	analyst	NN	13	appos
17	with	IN	16	prep
18	Montgomery	NNP	19	nn
19	Securities	NNPS	17	pobj
20	in	IN	19	prep
21	San	NNP	22	nn
22	Francisco	NNP	20	pobj
23	.	.	11	punct

1	Genentech	NNP	2	nsubj
2	faces	VBZ	0	root
3	competition	NN	2	dobj
4	in	IN	3	prep
5	the	DT	7	det
6	cardiac-drug	JJ	7	amod
7	market	NN	4	pobj
8	from	IN	3	prep
9	SmithKline	NNP	10	nn
10	Beecham	NNP	11	nn
11	PLC	NNP	14	poss
12	's	POS	11	possessive
13	heart	NN	14	nn
14	drug	NN	15	nn
15	Eminase	NNP	8	pobj
16	,	,	15	punct
17	expected	VBN	15	partmod
18	to	TO	19	aux
19	receive	VB	17	xcomp
20	market	NN	21	nn
21	approval	NN	19	dobj
22	shortly	RB	19	advmod
23	.	.	2	punct

1	And	CC	5	cc
2	Genentech	NNP	5	nsubj
3	is	VBZ	5	cop
4	n't	RB	5	neg
5	likely	JJ	21	ccomp
6	to	TO	7	aux
7	have	VB	5	xcomp
8	any	DT	10	det
9	new	JJ	10	amod
10	products	NNS	11	nsubj
11	ready	JJ	7	xcomp
12	for	IN	11	prep
13	market	NN	12	pobj
14	until	IN	7	prep
15	at	IN	17	advmod
16	least	JJS	15	pobj
17	1992	CD	14	pobj
18	,	,	21	punct
19	Ms.	NNP	20	nn
20	Gilbert	NNP	21	nsubj
21	added	VBD	0	root
22	.	.	21	punct

1	``	``	24	punct
2	The	DT	3	det
3	company	NN	5	poss
4	's	POS	3	possessive
5	stock	NN	7	nsubj
6	is	VBZ	7	aux
7	trading	VBG	24	ccomp
8	at	IN	7	prep
9	40	CD	10	number
10	times	NNS	14	num
11	next	JJ	12	amod
12	year	NN	14	poss
13	's	POS	12	possessive
14	numbers	NNS	8	pobj
15	,	,	7	punct
16	and	CC	7	cc
17	that	DT	20	nsubj
18	's	VBZ	20	cop
19	too	RB	20	advmod
20	much	JJ	7	conj
21	,	,	24	punct
22	''	''	24	punct
23	she	PRP	24	nsubj
24	said	VBD	0	root
25	.	.	24	punct

1	On	IN	8	prep
2	the	DT	4	det
3	plus	JJ	4	amod
4	side	NN	1	pobj
5	,	,	8	punct
6	Genentech	NN	8	nsubj
7	is	VBZ	8	aux
8	benefiting	VBG	27	ccomp
9	from	IN	8	prep
10	a	DT	13	det
11	lower	JJR	13	amod
12	tax	NN	13	nn
13	rate	NN	9	pobj
14	due	JJ	15	mwe
15	to	TO	13	prep
16	its	PRP$	18	poss
17	research	NN	18	nn
18	outlays	NNS	15	pobj
19	,	,	13	punct
20	giving	VBG	13	partmod
21	a	DT	22	det
22	boost	NN	20	dobj
23	to	TO	20	prep
24	earnings	NNS	23	pobj
25	,	,	27	punct
26	she	PRP	27	nsubj
27	said	VBD	0	root
28	.	.	27	punct


